Myovant Sciences (MYOV) Files for $172.5M IPO

Myovant Sciences Ltd. (NYSE: MYOV) filed a registration with the U.S. SEC for an IPO of its common stock. The proposed maximum offering price is $172.5 million.

Underwriters on the offering are Citigroup, Cowen and Company, Evercore ISI, and Barclays.

Myovant Sciences is a "clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health diseases and other endocrine-related disorders. Our lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone, or GnRH, receptor antagonist." The company continued, "We are advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and advanced prostate cancer."

You May Also Be Interested In

• Gores Holdings XI closes $358.8M IPO on Nasdaq
• Western Union awaits final state approval to close Intermex deal
• Taysha Gene Therapies prices $200M public stock offering